Patient-Centered Research, Evidera, Seattle, WA, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
J Dermatolog Treat. 2023 Dec;34(1):2202288. doi: 10.1080/09546634.2023.2202288.
Patients with atopic dermatitis (AD) have low treatment satisfaction. In this study, we evaluated the humanistic burden, treatment satisfaction, and treatment expectations in patients with AD in the United States.
Adults with AD recruited through the National Eczema Association and clinical sites completed a web-based survey comprising the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD), Dermatology Life Quality Index; Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis; Treatment Satisfaction Questionnaire for Medication (TSQM); and answered questions on healthcare provider (HCP) visits, treatment history, and treatment goals. Descriptive analyses were performed to compare participants by severity.
Among 186 participants (mean [standard deviation] age 39.7 [15.3] years, 79.6% female), 26.9%, 44.6%, and 26.3% of the participants had mild, moderate, or severe AD, respectively, based on PO-SCORAD. Greater disease severity was associated with a greater impact on work and daily life, decreased TSQM scores, and increased HCP visits. Corticosteroid topical cream or ointment (53.8%) and oral antihistamines (31.2%) were most commonly used for the treatment of AD. Participants reported declining/stopping/changing AD treatment due to the potential for side effects or lack of efficacy. 'Leading normal lives' (28.0%) and 'being itch-free' (33.9%) were important treatment goals.
Individuals with AD, especially severe disease, face a considerable humanistic burden even while using treatment.
特应性皮炎(AD)患者的治疗满意度较低。本研究评估了美国 AD 患者的人文负担、治疗满意度和治疗期望。
通过国家湿疹协会和临床站点招募的 AD 成年患者完成了一项基于网络的调查,该调查包括患者导向的特应性皮炎评分(PO-SCORAD)、皮肤病生活质量指数;工作生产力和活动障碍问卷-特应性皮炎;治疗药物满意度问卷(TSQM);并回答了关于医疗保健提供者(HCP)就诊、治疗史和治疗目标的问题。根据 PO-SCORAD,对参与者进行了严重程度比较的描述性分析。
在 186 名参与者中(平均[标准差]年龄 39.7[15.3]岁,79.6%为女性),根据 PO-SCORAD,分别有 26.9%、44.6%和 26.3%的参与者患有轻度、中度或重度 AD。疾病严重程度越高,对工作和日常生活的影响越大,TSQM 评分越低,HCP 就诊次数越多。皮质类固醇外用乳膏或软膏(53.8%)和口服抗组胺药(31.2%)是最常用于治疗 AD 的药物。由于潜在的副作用或疗效缺乏,参与者报告因拒绝/停止/改变 AD 治疗。“过正常生活”(28.0%)和“无瘙痒”(33.9%)是重要的治疗目标。
AD 患者,尤其是严重疾病患者,即使在接受治疗时,也面临着相当大的人文负担。